Abstract 1421P
Background
Imaging reading for endpoint evaluation in clinical trials presents challenges in reproducibility and accuracy, limiting the use of novel endpoints beyond human capabilities. This analysis explored the feasibility of AI-powered intracranial response assessment and uncovered novel imaging prognosticators in the phase III CROWN study.
Methods
72 patients (40 patients in the crizotinib arm, 32 patients in the lorlatinib arm) with CNS metastases at baseline in the CROWN study (NCT03052608) underwent intracranial response assessment using MRI at screening and then every 8 weeks until disease progression. VBrain, an FDA-approved brain tumor AI, was used to generate response assessments that were compared with those performed by 2 neuro-radiologists from the blinded independent central review group for the study using modified RECIST (mRECIST). The sum of tumor diameter changes at first on-treatment tumor scan from baseline, denoted as early tumor shrinkage (ETS), was assessed with Cox's proportional hazard model to estimate drug efficacy.
Results
For target lesion measurements, AI showed a high correlation with the independent readers (Pearson correlation coefficient ρ=0.94). The intracranial objective response rate assessed by AI was 27.5% and 71.9% in the crizotinib and lorlatinib arms, respectively. Among 666 time-point assessments, discordance rates were 35.1% between AI and reader 1, 33.5% between AI and reader 2, and 35.7% between the 2 readers. The time to intracranial progression (iTTP) derived from AI and human readers showed no significant difference by log-rank test. AI tracked 394 tumors beyond mRECIST, with a median ETS of -41.8% for all these lesions vs -24.4% for target lesions by mRECIST. Brain-wide ETS better predicted systemic TTP (HR 0.40, [95% CI 0.21–0.76], p<0.01), while target-lesion ETS showed no significant difference (HR 0.59, [95% CI 0.32–1.09], p=0.09) by ETS categories > or <= to median ETS.
Conclusions
There was high agreement between AI and readers in lesion measurement, response assessment, and endpoint evaluations in the CROWN study. ETS leveraging all brain lesions may uncover a potential prognostic indicator of response in ALK-positive advanced NSCLC patients.
Clinical trial identification
NCT03052608. Last update posted: May 31, 2022.
Editorial acknowledgement
Legal entity responsible for the study
Vysioneer Inc.
Funding
Vysioneer Inc.
Disclosure
C. Duan, A. Schayowitz, P. Selaru, K.D. Wilner: Financial Interests, Personal and Institutional, Full or part-time Employment: Pfizer Inc. Y. Chang, C. Liang, P. Chiang, V. Lin, Y. Yang, J. Lu: Financial Interests, Personal, Full or part-time Employment: Vysioneer Inc. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20